Literature DB >> 23582684

The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.

Guangzhi Gu1, Xiaoling Gao, Quanyin Hu, Ting Kang, Zhongyang Liu, Mengyin Jiang, Deyu Miao, Qingxiang Song, Lei Yao, Yifan Tu, Zhiqing Pang, Hongzhuan Chen, Xinguo Jiang, Jun Chen.   

Abstract

Low permeability across the blood-brain tumor barrier (BTB) and poor penetration into the glioma parenchyma represent key obstacles for anti-glioblastoma drug delivery. In this study, MT1-AF7p peptide, which presents high binding affinity to membrane type-1 matrix metalloproteinase (MT1-MMP) that over-expressed on both angiogenic blood vessels and glioma cells, was employed to decorate the paclitaxel-loaded PEG-PLA nanoparticles (MT1-NP-PTX) to mediate glioblastoma targeting. Tumor-homing and penetrating peptide iRGD was co-administrated to further facilitate nanoparticles extravasation from the tumor vessels and penetration into the glioma parenchyma. MT1-NP-PTX showed satisfactory encapsulated efficiency, loading capacity and size distribution. In C6 glioma cells, MT1-NP was found to exhibit significantly enhanced cellular accumulation than that of unmodified NP via both energy-dependent macropinocytosis and lipid raft-mediated endocytosis. The anti-proliferative and apoptosis-induction activity of PTX was significantly enhanced following its encapsulation in MT1-NP. In vivo imaging and glioma distribution together confirmed that MT1-AF7p functionalization and iRGD co-administration significantly improved the nanoparticles extravasation across BTB and accumulation in glioma parenchyma. Furthermore, in vitro C6 glioma spheroid assays evidenced that MT1-NP effectively penetrated into the glioma spheroids and significantly improved the growth inhibitory effects of loaded PTX on glioma spheroids. More importantly, the median survival time of those nude mice bearing intracranial C6 glioma received MT1-NP-PTX and iRGD combination regimen was 60 days, significantly longer than that of other groups. The findings suggested that the BTB/glioma cells dual-targeting DDS co-administrated with iRGD peptide might provide a both practical and feasible solution to highly efficient anti-glioblastoma drug delivery.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23582684     DOI: 10.1016/j.biomaterials.2013.03.036

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  37 in total

1.  Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models.

Authors:  Benjamin B Kasten; Ke Jiang; Denzel Cole; Aditi Jani; Neha Udayakumar; G Yancey Gillespie; Guolan Lu; Tingting Dai; Eben L Rosenthal; James M Markert; Jianghong Rao; Jason M Warram
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-26       Impact factor: 9.236

2.  iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Authors:  Lorena Simón-Gracia; Hedi Hunt; Pablo Scodeller; Jens Gaitzsch; Venkata Ramana Kotamraju; Kazuki N Sugahara; Olav Tammik; Erkki Ruoslahti; Giuseppe Battaglia; Tambet Teesalu
Journal:  Biomaterials       Date:  2016-07-20       Impact factor: 12.479

3.  Targeted drug delivery using iRGD peptide for solid cancer treatment.

Authors:  Xiangsheng Liu; Jinhong Jiang; Ying Ji; Jianqin Lu; Ryan Chan; Huan Meng
Journal:  Mol Syst Des Eng       Date:  2017-08-16

4.  A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.

Authors:  Kazuki N Sugahara; Pablo Scodeller; Gary B Braun; Tatiana Hurtado de Mendoza; Chisato M Yamazaki; Michael D Kluger; Joji Kitayama; Edwin Alvarez; Stephen B Howell; Tambet Teesalu; Erkki Ruoslahti; Andrew M Lowy
Journal:  J Control Release       Date:  2015-06-11       Impact factor: 9.776

5.  Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor.

Authors:  Jason Boyang Wu; Changhong Shi; Gina Chia-Yi Chu; Qijin Xu; Yi Zhang; Qinlong Li; John S Yu; Haiyen E Zhau; Leland W K Chung
Journal:  Biomaterials       Date:  2015-07-16       Impact factor: 12.479

6.  Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.

Authors:  Emily Wonder; Lorena Simón-Gracia; Pablo Scodeller; Ramsey N Majzoub; Venkata Ramana Kotamraju; Kai K Ewert; Tambet Teesalu; Cyrus R Safinya
Journal:  Biomaterials       Date:  2018-03-02       Impact factor: 12.479

7.  Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.

Authors:  Hong-Jun Cho; Sung-Jin Lee; Sung-Jun Park; Chang H Paik; Sang-Myung Lee; Sehoon Kim; Yoon-Sik Lee
Journal:  J Control Release       Date:  2016-06-24       Impact factor: 9.776

Review 8.  Crossing the barrier: treatment of brain tumors using nanochain particles.

Authors:  Efstathios Karathanasis; Ketan B Ghaghada
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-09

9.  Systemic delivery of blood-brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue.

Authors:  Jennifer K Saucier-Sawyer; Yang Deng; Young-Eun Seo; Christopher J Cheng; Junwei Zhang; Elias Quijano; W Mark Saltzman
Journal:  J Drug Target       Date:  2015       Impact factor: 5.121

Review 10.  Tumor penetrating peptides for improved drug delivery.

Authors:  Erkki Ruoslahti
Journal:  Adv Drug Deliv Rev       Date:  2016-04-01       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.